Cargando…

Recombinant Human C1 Esterase Inhibitor for the Management of Adverse Events Related to Intravenous Immunoglobulin Infusion in Patients With Common Variable Immunodeficiency or Polyneuropathy: A Pilot Open-Label Study

It has been hypothesized that low levels of C1 esterase inhibitor (C1-INH), a key inhibitor of the complement pathway, may play a role in the occurrence of adverse events (AEs) associated with intravenous immunoglobulin (IVIG) therapy. This open-label pilot study evaluated C1-INH replacement, with r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Melamed, Isaac R., Miranda, Holly, Heffron, Melinda, Harper, Joseph R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962274/ https://www.ncbi.nlm.nih.gov/pubmed/33737935 http://dx.doi.org/10.3389/fimmu.2021.632744

Ejemplares similares

Evaluation of Intravenous Immunoglobulin in Pediatric Acute-Onset Neuropsychiatric Syndrome
por: Melamed, Isaac, et al.
Publicado: (2021)

Intravenous immunoglobulin for inflammatory demyelinating polyneuropathy
por: Talaei, M., et al.
Publicado: (2021)

Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency
por: Wasserman, Richard L., et al.
Publicado: (2016)

Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga®) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study
por: Borte, Michael, et al.
Publicado: (2017)

Adverse events of intravenous immunoglobulin infusions: a ten-year retrospective study
por: Palabrica, Frances Rose R., et al.
Publicado: (2013)

Overview of the pathogenesis and treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulins
por: Mahdi-Rogers, Mohamed, et al.
Publicado: (2010)

Attention Deficit Disorder and Allergic Rhinitis: Are They Related?
por: Melamed, Isaac, et al.
Publicado: (2016)

Safety, Efficacy and Pharmacokinetics of a New 10% Liquid Intravenous Immunoglobulin (IVIG) in Patients with Primary Immunodeficiency
por: Wasserman, Richard L., et al.
Publicado: (2012)

A Retrospective Observational Study of Adverse Reactions Associated With Intravenous Immunoglobulin Infusion
por: Kato, Hidefumi, et al.
Publicado: (2021)

Safety and Tolerability of Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: Results of the ProCID Study
por: Cornblath, David R., et al.
Publicado: (2023)

Measuring disease activity and predicting response to intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy
por: Khoo, Anthony, et al.
Publicado: (2019)

Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trial
por: Kuwabara, Satoshi, et al.
Publicado: (2017)

Subcutaneous Immunoglobulin 16.5% (Cutaquig®) in Primary Immunodeficiency Disease: Safety, Tolerability, Efficacy, and Patient Experience with Enhanced Infusion Regimens
por: Gupta, Sudhir, et al.
Publicado: (2023)

Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre‐randomization phase of the Polyneuropathy And Treatment with Hizentra study
por: Mielke, Orell, et al.
Publicado: (2019)

Early treatment with intravenous immunoglobulins in patients with critical illness polyneuropathy: a randomized controlled, double-blinded study
por: Brunner, R, et al.
Publicado: (2012)

Subcutaneous immunoglobulin in primary immunodeficiency – impact of training and infusion characteristics on patient-reported outcomes
por: Mallick, R., et al.
Publicado: (2020)

Aseptic meningitis following intravenous immunoglobulin therapy of common variable immunodeficiency
por: Kaarthigeyan, K., et al.
Publicado: (2011)

Aseptic meningitis following intravenous immunoglobulin therapy of common variable immunodeficiency
por: Bhatt, Girish Chandra, et al.
Publicado: (2012)

Does Intravenous Immunoglobulin Therapy Prolong Immunodeficiency in Transient Hypogammaglobulinemia of Infancy?
por: Memmedova, Lale, et al.
Publicado: (2013)

Timing of infections in patients with primary immunodeficiencies treated with intravenous immunoglobulin (IVIg)
por: Gill, Parwinder K., et al.
Publicado: (2018)

Combined intravenous immunoglobulin and methylprednisolone as induction treatment in chronic inflammatory demyelinating polyneuropathy (OPTIC protocol): a prospective pilot study
por: Adrichem, M. E., et al.
Publicado: (2019)

Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada
por: Blackhouse, Gord, et al.
Publicado: (2010)

Two comparative assessments of intravenous immunoglobulin therapy switching patterns in the treatment of chronic inflammatory demyelinating polyneuropathy in the US
por: Guptill, Jeffrey T, et al.
Publicado: (2019)

Is It Safe to Switch From Intravenous Immunoglobulin to Subcutaneous Immunoglobulin in Patients With Common Variable Immunodeficiency and Autoimmune Thrombocytopenia?
por: Scheuerlein, Philipp, et al.
Publicado: (2018)

Efficient management of secondary haemophagocytic lymphohistiocytosis with intravenous steroids and γ-immunoglobulin infusions
por: Georgiadou, Sarah, et al.
Publicado: (2019)

Fluctuations in quality of life and immune responses during intravenous immunoglobulin infusion cycles
por: Abbott, Jordan K., et al.
Publicado: (2022)

Low rates of headache and migraine associated with intravenous immunoglobulin infusion using a 15-minute rate escalation protocol in 123 patients with primary immunodeficiency
por: Geng, Bob, et al.
Publicado: (2023)

Immunoglobulin replacement therapy in patients with immunodeficiencies: impact of infusion method on patient-reported outcomes
por: Mallick, Rajiv, et al.
Publicado: (2022)

Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies
por: Perez, Elena E., et al.
Publicado: (2021)

Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects with Primary Immunodeficiency Disease
por: Wasserman, Richard L., et al.
Publicado: (2016)

Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients
por: Schroeder, H. W., et al.
Publicado: (2012)

Chronic inflammatory demyelinating polyneuropathy (CIDP): change of serum IgG dimer levels during treatment with intravenous immunoglobulins
por: Ritter, Christian, et al.
Publicado: (2015)

Severe Chronic Inflammatory Demyelinating Polyneuropathy Ameliorated following High-dose (3 g/kg) Intravenous Immunoglobulin Therapy
por: Seino, Yusuke, et al.
Publicado: (2018)

Subcutaneous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy
por: Goyal, Namita A., et al.
Publicado: (2021)

Non-ST Elevation Myocardial Infraction after High Dose Intravenous Immunoglobulin Infusion
por: Mizrahi, Meir, et al.
Publicado: (2009)

Intravenous Immunoglobulin Monotherapy for Granulomatous Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency
por: Hasegawa, Mizue, et al.
Publicado: (2017)

Adverse Reactions to Intravenous Immunoglobulins - Our Experience
por: Kareva, Lidija, et al.
Publicado: (2018)

Transfusion-related acute lung injury associated to intravenous immunoglobulin infusion in a pediatric patient
por: Pegler, José Roberto Mendes, et al.
Publicado: (2020)

Delivery of subcutaneous immunoglobulin by rapid “push” infusion for primary immunodeficiency patients in Manitoba: a retrospective review
por: Walter, Graham, et al.
Publicado: (2020)

Fatigue, depression, and product tolerability during long-term treatment with intravenous immunoglobulin (Gamunex® 10%) in patients with chronic inflammatory demyelinating polyneuropathy
por: Klehmet, Juliane, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9vq7t5al12mdpjpo9s84fcjcdd